LMFA vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

LMFA

51.2
AI Score
VS
HIVE Wins

HIVE

56.4
AI Score

Investment Advisor Scores

LMFA

51score
Recommendation
HOLD

HIVE

56score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric LMFA HIVE Winner
Forward P/E 0 62.8931 Tie
PEG Ratio 0 0 Tie
Revenue Growth -27.3% 130.5% HIVE
Earnings Growth -89.4% -99.9% LMFA
Tradestie Score 51.2/100 56.4/100 HIVE
Profit Margin 0.0% -49.9% LMFA
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

LMFA 1M: +1324.7% · 3M: +808.1% HIVE 1M: -18.2% · 3M: +17.4%

Current Technical Phase

LMFA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (129.1% over 20 days), RSI 81

RSI (14): 80.7 · Price: $2.60

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 42

RSI (14): 42.0 · Price: $2.83

Fundamentals Snapshot

Metric LMFA HIVE
Market Cap
Forward P/E -0.2 -5.5
Trailing P/E
Revenue (TTM)
Revenue Growth -0.3% 1.3%
Gross Margin 0.0% 0.4%
Operating Margin -4.5% -0.8%
EPS -67.50 -0.78
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.